Can less be more? prostate cancer drug dose study aims to cut side effects
NCT ID NCT05276492
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 25 times
Summary
This study looked at whether a lower dose of the prostate cancer drug abiraterone can still control the disease. About 50 men with prostate cancer who were starting abiraterone for the first time took part. The goal was to find the smallest effective dose by measuring hormone levels and PSA over 12 weeks, potentially reducing side effects while keeping the cancer in check.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.